(15051017), S. Y. O., (15051020), Y. W. L., (15051023), E. J. L., (15051026), J. H. K., (15051029), Y. P., (15032490), S. G. H., . . . (15032484), M. R. Y. (2025). Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.
Cytowanie według stylu Chicago (wyd. 17)(15051017), Seung Yeon Oh, et al. Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC. 2025.
Cytowanie według stylu MLA (wyd. 9)(15051017), Seung Yeon Oh, et al. Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC. 2025.